Artiva Biotherapeutics, Inc.
ARTV
$1.98
-$0.07-3.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 3.41% | 2.89% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.37% | -0.37% | |||
| Operating Income | -21.37% | 0.37% | |||
| Income Before Tax | -26.19% | 7.88% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -26.19% | 7.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -26.19% | 7.88% | |||
| EBIT | -21.37% | 0.37% | |||
| EBITDA | -22.04% | 0.31% | |||
| EPS Basic | -26.42% | 28.62% | |||
| Normalized Basic EPS | 41.08% | -53.16% | |||
| EPS Diluted | 36.86% | -42.93% | |||
| Normalized Diluted EPS | 41.08% | -53.16% | |||
| Average Basic Shares Outstanding | -0.18% | 29.05% | |||
| Average Diluted Shares Outstanding | -0.18% | 29.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||